Full Committee Hearing on The Trump Administration's Response to the Drug Crisis: Part II
Washington, D.C. (May 10, 2019)—On Thursday, the Committee on Oversight and Reform held a hearing on “The Trump Administration’s Response to the Drug Crisis, Part II.”
- ONDCP Director Carroll commended the “heart and spirit” of the CARE Act introduced by Chairman Cummings and all Democratic Members of the Committee. This legislation, which has been endorsed by more than 200 groups, would provide stable, predictable funding to the states and localities hardest hit by the drug crisis to expand access to treatment.
- In response to the Committee’s request made during the “Trump Administration's Response to the Drug Crisis” hearing, ONDCP provided several supplements to the National Drug Control Strategy that was issued in January of this year. After failing to publish a strategy in both 2017 and 2018, the document issued by ONDCP in January was found by the GAO to lack key information required by statute.
- Delaware Division of Public Health Director Dr. Karyl Rattay spoke to the critical role of the Affordable Care Act and Medicaid expansion in ensuring access to substance use disorder treatment. She stated “We have great concerns that if the ACA were repealed and we went backwards in terms of Medicaid expansion, many people would lose access to lifesaving treatment services.”
Office of National Drug Control Policy
Acting Director, Homeland Security and Justice
Government Accountability Office
Delaware Division of Public Health
Brevard County, FL
Watch ONDCP Director commend the CARE Act.
Watch Rep. Connolly’s question line.
Watch Rep. Khanna’s question line.
Watch Rep. Hill’s question line.